Asiatic Laboratories (DHA:ASIATICLAB) YoY EBITDA Growth: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ASIATICLAB Asiatic Laboratories Ltd DHA:ASIATICLAB
32 GF Score
Price BDT123.70
! 1 Warning Sign
View Full Analysis

What is Asiatic Laboratories YoY EBITDA Growth?

Asiatic Laboratories DHA:ASIATICLAB -3.06% 32 YoY EBITDA Growth is 0.00% as of . 20. GuruFocus rates DHA:ASIATICLAB with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Asiatic Laboratories's YoY EBITDA Growth for the quarter that ended in . 20 was 0.00%.

Asiatic Laboratories's EBITDA per Share for the six months ended in . 20 was BDT0.00.

Asiatic Laboratories YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Asiatic Laboratories's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asiatic Laboratories YoY EBITDA Growth Chart

Asiatic Laboratories Annual Data
Trend
YoY EBITDA Growth

Asiatic Laboratories Semi-Annual Data
YoY EBITDA Growth
DHA:ASIATICLAB
32GF Score
Asiatic Laboratories Ltd DHA:ASIATICLAB
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Asiatic Laboratories YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Asiatic Laboratories's YoY EBITDA Growth for the fiscal year that ended in . 20 is calculated as:

YoY EBITDA Growth (A: . 20 )
=(EBITDA per Share (A: . 20 )-EBITDA per Share (A: . 20 ))/ | EBITDA per Share (A: . 20 ) |
=(-)/ | |
=N/A %

Asiatic Laboratories's YoY EBITDA Growth for the quarter that ended in . 20 is calculated as:

YoY EBITDA Growth (Q: . 20 )
=(EBITDA per Share (Q: . 20 )-EBITDA per Share (Q: . 20 )) / | EBITDA per Share (Q: . 20 ) |
=(-)/ | |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Asiatic Laboratories (DHA:ASIATICLAB) has a YoY EBITDA Growth of 0.00% as of . 20. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Asiatic Laboratories and its competitors.
Is Asiatic Laboratories' YoY EBITDA Growth too high?
Asiatic Laboratories' current YoY EBITDA Growth is 0.00%. Overall, Asiatic Laboratories has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Asiatic Laboratories' YoY EBITDA Growth compare to ZTS and UTHR?
Asiatic Laboratories' YoY EBITDA Growth of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Asiatic Laboratories and its competitors. Asiatic Laboratories's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asiatic Laboratories stock overvalued right now?
Asiatic Laboratories (DHA:ASIATICLAB) has a current YoY EBITDA Growth of 0.00%. The current YoY EBITDA Growth is 0.00%. Asiatic Laboratories' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Asiatic Laboratories (DHA:ASIATICLAB), the current YoY EBITDA Growth is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Asiatic Laboratories Business Description

Address Siddeshwari Circular Road, 42-43, Treasure Island (5 th Floor) Shantinagar, Dhaka, BGD, 1217
Asiatic Laboratories Ltd is engaged in manufacturing and marketing of a wide range of the rapeutical medicines pharmaceutical products in the categories of Biological, Non-Biological & Sterile Pharmaceutical dosage. It has 80 generic molecules comprising therapeutic classes like antibiotics, antihistamines, bronchodilators, vitamins-minerals, antiulcerants, laxatives, gastroprokinetics, antihematinic, anthelmentics, CNS drugs, respiratory drugs, NSAIDs, dermatological preparations and sterile ophthalmic preparations.
32GF Score

Get the complete analysis for DHA:ASIATICLAB

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT123.70
Price